NCT05725421Not yet recruiting

Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy

Name: Clinical Trial NCT05725421
Creator: Case Comprehensive Cancer Center
Keywords: Renal Cell Carcinoma, Donor Radical and Partial Nephrectomy, procedure, clinical trial, United States of America

Oncologic, Functional and Surgical Outcomes for Patients Undergoing Radical Nephrectomy for Low-Risk Renal Cell Carcinoma and Recipients of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy

Case Comprehensive Cancer CenterClinicalTrials.govprocedure

Verified

Study focus

Disease/Condition: Renal Cell Carcinoma
Drug/Device/Intervention: Donor Radical and Partial Nephrectomy
Study type: Interventional
Intervention type: procedure

Sponsor & location

Primary sponsor: Case Comprehensive Cancer Center
Location: Cleveland, United States of America

Timeline & enrollment

Phase: N/A
Start date: Jul 01, 2023
End date: Jul 01, 2024
Enrollment: 5 participants

Primary outcome

Safety and Feasibility of Radical Nephrectomy for a Small Renal Mass,Safety and feasibility for Renal Transplant Participants Receiving a Reconstructed Donor Kidney

Summary

This study is designed to investigate a novel approach to offer more ESRD participants the benefits associated with renal transplantation by increasing the supply of available allografts

ICD-10 classifications

Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05725421
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05725421 through Pure Global AI's free database. This phase not specified trial is sponsored by Case Comprehensive Cancer Center and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 5 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.